Characterization of population genetic structure of hereditary transthyretin amyloidosis in Bulgaria
- 2 June 2021
- journal article
- research article
- Published by Taylor & Francis in Amyloid
- Vol. 28 (4) , 219-225
Abstract
The hereditary transthyretin amyloidosis (ATTRv amyloidosis) is an autosomal dominant genetic disease characterized by amyloid formation in different tissues due to pathogenic variants in the TTR gene. Great heterogeneity in the penetrance and manifestation of ATTRv amyloidosis is observed. In Bulgaria, the most common TTR pathogenic variant is Glu89Gln. Other TTR pathogenic variants are also found – Val30Met, Ser77Phe, Gly47Glu and Ser52Pro. There is a proven founder effect for the Glu89Gln variant, thus the aim of the present study is to investigate the founder effect for the other TTR pathogenic variants in Bulgaria. Haplotype analysis was performed by using microsatellite markers close to the TTR gene. DNA samples from ATTRv amyloidosis patients and their healthy relatives were analyzed. Theoretical haplotype reconstruction was done with Arlequin v.3.01 software. The age of the most recent common ancestor (hypothetical founder) for the studied variants was calculated with the DMLE 2.2 software. In addition, DBS screening among 100 Roma newborns was done for the Gly47Glu TTR variant via direct Sanger sequencing. The reconstructed haplotypes of the patients were compared to their healthy relatives and to a control group of 40 healthy individuals. The results showed a possible founder effect for each of the studied variants. The Val30Met haplotype was compared to published haplotype data for this variant and no similarity was found. The result from the DBS screening showed no pathogenic TTR variants in exon 2 of the gene, so we considered the presence of the Gly47Glu variant in our population a sporadic event. With this study, we succeeded to gain a more complete picture of the population genetics of ATTRv amyloidosis in Bulgaria and made another step towards a more detailed understanding of the disease epidemiology.Keywords
Funding Information
- Pfizer (WI241542/2018)
This publication has 29 references indexed in Scilit:
- Guideline of transthyretin-related hereditary amyloidosis for cliniciansOrphanet Journal of Rare Diseases, 2013
- TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance?European Journal of Human Genetics, 2010
- Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: A single-center experienceLiver Transplantation, 2010
- Linkage disequilibrium — understanding the evolutionary past and mapping the medical futureNature Reviews Genetics, 2008
- On the Origin of the Transthyretin Val30Met Familial Amyloid PolyneuropathyAnnals of Human Genetics, 2008
- Reconstructing the Genealogy of a BRCA1 Founder Mutation by Phylogenetic AnalysisAnnals of Human Genetics, 2008
- Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish populationAmyloid, 2008
- Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)‐type I in Póvoa do Varzim and Vila do Conde (north of Portugal)American Journal of Medical Genetics, 1995
- A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected.Journal of Medical Genetics, 1994
- Familial Amyloidotic Polyneuropathy in Sweden: Geographical Distribution, Age of Onset, and PrevalenceHuman Heredity, 1993